Non Small Cell Lung Cancer Clinical Trials in Louisville, Kentucky

13 studies are recruiting for non small cell lung cancer in Louisville, Kentucky right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

   The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-l…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Louisville, Kentucky

   Locations

   328 in total

   Run by

   AstraZeneca

   See if you can join NCT06692738 on ClinicalTrials.gov

2. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

   The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Norton Cancer Institute Research, Louisville, Kentucky

   Locations

   29 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06303505 on ClinicalTrials.gov

3. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

   The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The University of Louisville, James Graham Brown Cancer Center ( Site 0037), Louisville, Kentucky

   Locations

   229 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06077760 on ClinicalTrials.gov

4. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

   This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Norton Cancer Institute, Louisville, Kentucky

   Locations

   42 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT04198766 on ClinicalTrials.gov

5. Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

   This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Norton Cancer Institute, Louisville, Kentucky

   Locations

   45 in total

   Run by

   BioNTech SE

   See if you can join NCT05142189 on ClinicalTrials.gov

6. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

   This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville, Kentucky

   Locations

   10 in total

   Run by

   Obsidian Therapeutics, Inc.

   See if you can join NCT06060613 on ClinicalTrials.gov

7. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Norton Cancer Institute /ID# 248903, Louisville, Kentucky

   Locations

   48 in total

   Run by

   AbbVie

   See if you can join NCT05005403 on ClinicalTrials.gov

8. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

   This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Baptist Health, Louisville, Kentucky

   Locations

   26 in total

   Run by

   Teligene US

   See if you can join NCT05168566 on ClinicalTrials.gov

9. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

   The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Norton Cancer Institute - Downtown, Louisville, Kentucky

   Locations

   9 in total

   Run by

   Teligene US

   See if you can join NCT06010329 on ClinicalTrials.gov

10. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

    To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Louisville Physicians, Louisville, Kentucky

    Locations

    50 in total

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT02468024 on ClinicalTrials.gov

11. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Norton Cancer Institute, Louisville, Kentucky

    Locations

    39 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

12. A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

    This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations，uncommon mutations, classical mutations (Ex19del …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Louisville, Kentucky

    Locations

    7 in total

    Run by

    Avistone Biotechnology Co., Ltd.

    See if you can join NCT06046495 on ClinicalTrials.gov

13. The Effect of Beta-glucan in Non-Small Cell Lung Cancer

    The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    James Graham Brown Cancer Center, Louisville, Kentucky

    Run by

    University of Louisville

    See if you can join NCT00682032 on ClinicalTrials.gov